Pharma giant Sanofi-Aventis has said that the experimental diabetes drug lixisenatide has shown significant success in lowering a key measure of blood glucose and blood sugar, as well as body weight, during a late stage trial. The results from the trial follow on from previous success in earlier trials into the drug.
The trial results are a further positive measure for the effectiveness of the drug in reducing levels of blood sugar in people suffering from type 2 diabetes . The trial also revealed that lixisenatide did not substantially raise the risk of symptomatic hypoglycemia, as compared to that of a placebo .
The study on lixisenatide, a GLP-1 class of drugs that stimulate insulin release when levels of glucose get too high, is the most recent in a broader programme by the company to offer more effective therapies for diabetes patients, which includes their insulin gargline Lantus, a long-acting basal insulin analogue. Sanofi-Aventis have also recently bought out the American biotech firm Genzymen, and put in place a new diabetes division.
If the drug achieves marketing approval, it will provide an alternative to Victoza, developed by Novo Nordisk, and Byetta, which is produced by Amylin .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…